NAME: Jianhua Yu, Ph - Ohio State University€¦ · Web [email protected]. ... World...

Jianhua Yu, PhD Updated: 05/31/2016

Jianhua Yu, PhD

General Information

The Ohio State University Biomedical Research TowerRoom 816, 460 West 12th AvenueColumbus, OH 43210614-293-1471 (office)614-688-7594 (Lab)[email protected]

Education

2003 Ph.D. Molecular Biology, Purdue University, West Lafayette, Indiana

2005 Postdoc Immunology and Cancer Biology, College of Medicine, Comprehensive

Cancer Center, James Cancer Hospital, Columbus, Ohio

Current Position

2015-present Associate Professor with Tenure, Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University.

Research Areas

NK cell biology, chimeric antigen receptor (CAR) NK and CAR T cells, oncolytic virus, gene regulation and cell signaling in immune response and malignant transformation, blood and marrow stem cell transplantation, immuno-cellular therapy or oncolytic virotherapy for acute myeloid leukemia, multiple myeloma, glioblastoma, etc.

Professional Experience and Academic Appointments

2011-2015 Assistant Professor, Division of Hematology, Department of Internal Medicine, College of

Medicine, The Ohio State University.

2007-2011 Research Scientist, Division of Hematology, Department of Internal Medicine, College of

Medicine, The Ohio State University.

2005-2006 Research Associate, Department of Molecular Virology, Immunology and Medical

Genetics, College of Medicine, The Ohio State University.

2003-2005 Postdoctoral Researcher, The Ohio State University Comprehensive Cancer Center.

2001-2003 Research Assistant, Purdue University.

Honors and Awards

1


National

2015 Jack Latham Memorial Award for Innovative Research, the National Blood Foundation

2015 Research Scholar, the American Cancer Society

2015 Gabrielle's Angel Foundation Medical Award

2012 Scientific Research Grant Recipient, the National Blood Foundation

2004 ASH Travel Award, the American Society of Hematology

Institutional

2015 FAME Faculty of the Year Award for Researchers, College of Medicine, The Ohio State

University

2012 Institutional Research Grantee, the American Cancer Society

2003-2004 Up on the Roof Postdoctoral Fellowship, the James Cancer Hospital, The Ohio StateUniversity

Professional Memberships and Activities

2015- Member, The International Society for Natural Immunity

2014- Member, The Asia-Pacific Blood and Marrow Transplantation Organization (APBMT)

2012- Member, The International Association of Comparative Research on Leukemia

and Related Diseases (IACRLRD)

2011- Member, The American Association of Blood Banks (AABB)

2011- Member, The Ohio State University Comprehensive Cancer Center (OSUCCC)

2005- Member, The American Association for Cancer Research (AACR)

2005- Member, The American Society of Hematology (ASH)

Educational Activities Teaching at The Ohio State University

2016 Biomedical Sciences Graduate Program (BSGP) 8800: Cancer Biology and Therapeutics

2016 The Integrated Biomedical Science Graduate Program (IBGP) 7040: Research Problem

Solving in Biomedical Science

2016 Pathology/Veterinary Biosciences 6640: Fundamentals of Oncology

2015 Adoptive Cell Transfer, Basic Science Lecture for Fellows



2


2015 The immunology part of Biomedical Engineering 5310 – Advanced Biomaterials

2014 MVIMG (Molecular Virology, Immunology & Medical Genetics) 8010: Cancer Immunology



2014 The immunology part of Biomedical Engineering 5310 – Advanced Biomaterials

2014 Biology 4998: Undergraduate Research

2014 Pathology 850: Seminar in Pathology and Clinical Pathology (Immunology)



2013 Pathology 850: Seminars in Pathology

2013 IBGP 7930: Individual Studies in Integrated Biomedical Science (Laboratory Rotations)

2013 MCDB 7780: Molecular, Cellular, and Developmental Biology (MCDB) Interdisciplinary

Graduate Program Laboratory Rotations

2012 The immunology part of Biomedical Engineering (BME) 5310 – Advanced Biomaterials

2012 IBGP 7060: Faculty Research in Biomedical Science

2012 Pathology 850: Seminars in Pathology

2011 Biology 4998: Undergraduate Research

Editorial Board Services

2015- Member, Journal of Cancer Biology and Treatment

2014- Member, Journal of Cellular Immunotherapy

2013- Academic Editor, PLOS ONE

2012- Member, American Journal of Translational Research

2012- Member, Scientifica-Hematology

Ad Hoc Journal Referee

2016-present Reviewer, Nature Reviews Immunology

2016-present Reviewer, Science Translational Medicine

2016-present Reviewer, Clinical Cancer Research

2016-present Reviewer, Current Medicinal Chemistry

2016-present Reviewer, Journal of Video Experiments

2016-present Reviewer, Journal of Hematology and Oncology

2016-present Reviewer, Molecular and Cellular Biochemistry

2015-present Reviewer, Scientific Reports (Nature Publisher)

2015-present Reviewer, Oncotarget

2015-present Reviewer, Oncoimmunology

3


2015-present Reviewer, Cancer Immunology Research

2015-present Reviewer, Innate Immunity

2014-present Reviewer, Haematologica

2014-present Reviewer, Blood and Marrow Transplantation

2014-present Reviewer, BMC Cancer

2014-present Reviewer, Immunity

2013-present Reviewer, International Immunopharmacology

2013-present Reviewer, Scientifica-Hematology

2013-present Reviewer, World Journal of Pediatrics

2013-present Reviewer, PLoS One

2013-present Reviewer, Stem Cells

2012-present Reviewer, Leukemia Research

2011-present Reviewer, Apoptosis

2010-present Reviewer, Cancer Immunology and Immunotherapy

2010-present Reviewer, Immunotherapy (Future Medicine)

2009-present Reviewer, European Journal of Immunology

2005-present Reviewer, Blood2005-present Reviewer, Journal of Leukocyte Biology

Contributions to National/International Professional Organizations

2015 Abstract reviewer and session moderator, The 57th Annual Meeting of the American

Society of Hematology, the session of Lymphocytes, Lymphocyte Activation and

Immunodeficiency, including HIV and Other Infections II

2014 Co-chair, Translational Research Cancer Center Consortium (TRC3), Symposium II,

Seven Springs, Pennsylvania, United States

2013 Abstract review coordinator, The 55th Annual Meeting of the American Society of

Hematology

2013 Meeting session moderator, The 55th Annual Meeting of American Society of Hematology

2013 Abstract reviewer, The 55th Annual Meeting of the American Society of Hematology, the

session of Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV

and Other Infections II

2012 Meeting session moderator, The 54th Annual Meeting of American Society of Hematology

2012 Abstract reviewer, The 54th Annual Meeting of the American Society of Hematology, the session of Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections II

4


Journal Article Publications

1. Yu J , Marshall K, Yamaguchi M, et al. Microhomology-dependent end-joining and repair of transposon-induced DNA hairpin by host factors in Saccharomyces cerevisiae. Molecular and Cellular Biology. 2004 Feb; 24(3):1351-64. Highlighted in Faculty of 1000 Biology. PMCID: PMC321453.

2. Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, Yu J, Becknell B, Yu L, Liu C, Vukosavljevic T, Whitman SP, Chang KS, Byrd JC, Perrotti D, Plass C, Marcucci G. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Research. 2005 Feb; 65(4):1277-84. PMID: 15735013.

3. Trotta R, Parihar R, Y u J , Becknell B, Allard J, Wen J, Ding W, Mao H, Tridandapani S, Carson WE 3rd, Caligiuri MA. Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine co-stimulation. Blood. 2005 Apr 15; 105(8):3011-8. PMID: 15604218.

4. Becknell B*, Trotta R*, Yu J*, Ding W, Mao HC, Hughes T, Marburger T, and Caligiuri MA. Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector. Journal of Immunological Methods. 2005 Jan; 296(1-2):115-23. *These authors equally contributed to this paper. PMID: 15680156.

5. Fulci G, Breymann L, Gianni D, Rhee SS, Brat DJ, Stemmer-Rachamimov A, Yu J, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proceedings of the National Academy of Sciences of the United States of America. 2006 Feb 15; 103(34):12873-78.PMCID: PMC1568940.

6. Yu J , Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blaser BW, Sun J, Benson DM, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, Weinstein W, Marcucci G, Caligiuri MA. Pro- and anti-inflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity. 2006 May; 24(5):575-90. PMID: 16713975.Note: Commentary in Immunity by Dr. Howard A. Young, 2006, 24(5): 506-7. In news. Highlighted in Faculty of 1000 Biology.

7. Becknell B, Hughes T, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesús ML. Alghothani M, Benson Jr DM, Lehman A, Jarjoura D, Perrotti D, Bates MD, Caligiuri MA. Hlx homeobox transcription factor negatively regulates interferon- production in monokine-activated natural killer cells. Blood. 2007 Mar; 109(6): 2481-7. PMCID: PMC1852195.

8. Liu S, Klisovic RB, Vukosavljevic T, Yu J , Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D, Marcucci G. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. Journal of Pharmacology and Experimental Therapeutics. 2007 Jun; 321(3):953-60. PMID: 17389244.

9. Caligiuri MA, Briesewitz R, Yu J , Wang L, Wei M, Arnoczky KJ, Marburger T, Wen J, Perrotti D, Bloomfield CD, Whitman SP. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood. 2007 Aug; 110(3):1022-4. PMCID: PMC1924768.

10. Trotta R, Col JD, Allard J II, Neviani P, Santhanam R, Mao H, Becknell B, Y u J , Ferketich AK, Modi A, Blaser BW, Perrotti D, Caligiuri MA. The PP2A inhibitor SET regulates natural killer cell IFN- gene expression. Journal of Experimental Medicine. 2007 Oct; 204(10):2397-405. PMCID: PMC2118465.

5


11. Yu J *, Wei M, Boyd Z, Lehmann EB, Trotta R, Mao H, Becknell B, Jaung MS, Jarjoura D, Wu LC, Caligiuri MA*. Transcriptional control of human T-BET expression: the role of Sp1. European Journal of Immunology. 2007 Sept; 37(9):2549-61. PMID: 17705132. *Co-corresponding author.

12. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Klisovic RB, Baiocchi R, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, and Marcucci G. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008 Feb 15; 111(4):2364-73. PMCID: PMC2234064.

13. Kondadasula VS, Roda JM, Parihar R, Yu J , Caligiuri MA, Tridandapani S, Carson W 3rd. Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of Erk and enhanced production of IFN-gamma. Blood. 2008 Apr; 111(8):4173-83. PMCID: PMC2288725.

14. Trotta R, Col JD, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J 2nd, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. The Journal of Immunology. 2008 Sept; 81(6):3784-92. PMCID: PMC2924753.

15. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G. MicroRNA -29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009 Jan;113(17):4008-10. PMCID: PMC2710934.

16. Park IK, Giovenzana C, Hughes TL, Yu J, Trotta R, Caligiuri MA. The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. Blood. 2009 Mar; 113(11):2470-7. PMCID: PMC2656272.

17. Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, Li PK, Lin J, Fuchs JR, Marcucci G, Li C, Chan KK. Curcumin is a potent DNA hypomethylation agent. Bioorganic & Medicinal Chemistry Letters. 2009 Feb; 19(3):706-9. PMID: 19112019.

18. Benson DM Jr, Yu J, Becknell B, Wei M, Freud AG, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 2009 Mar; 113(12):2706-14. PMCID: PMC2661858.

19. Yu J *, Wei M, Mao H, Zhang J, Hughes T, Mitsui T, Park IK, Hwang C, Liu S, Marcucci G, Trotta R, Benson DM Jr, Caligiuri MA*. CD94 defines phenotypically and functionally distinct mouse NK cell subsets. The Journal of Immunology. 2009 Oct; 183(8):4968-74. PMCID: PMC2924742. *Co-corresponding author.

20. Hughes T, Becknell B, McClory S, Briercheck E, Freud AG, Zhang X, Mao H, Nuovo G, Yu J, Caligiuri MA. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood. 2009 Apr; 113(17):4008-10. PMCID: PMC2673127.

21. Yu J *, Ershler M, Yu L, Wei M, Hackanson B, Yokohama A, Mitsui T, Liu C, Mao H, Liu S, Liu Z, Trotta R, Liu CG, Liu X, Huang K, Visser J, Marcucci G, Plass C, Belyavsky AV, Caligiuri MA*. TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia. Blood. 2009 May; 113(22):5558-67. PMCID: PMC2689053. *Co-corresponding author.

6


22. Yokohama A, Mishra A, Mitsui T, Becknell B, Johns J, Curphey D, Blaser BW, Vandeusen JB, Mao H, Yu J, Caligiuri MA. A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. Leukemia Research. 2010 Feb; 4(2):203-9. PMCID: PMC2814907.

23. Schwartzbaum JA, Huang K, Lawler S, Ding B, Yu J, Chiocca EA. Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro-Oncology. 2010 Apr; 12(4):320-7. PMCID: PMC2940608.

24. Yu J *, Mao HC, Wei M, Hughes T, Zhang J, Park IK, Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA*. CD94 surface density identifies a functional intermediary between the CD56bright

and CD56dim human NK cell subsets. Blood. 2010 Jan; 115(2):274-81. PMCID: PMC2808153. *Co-corresponding author. Highlighted in Faculty of 1000 Biology.

25. Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, Caligiuri MA. In vivo role of Flt3 ligand and dendritic cells in natural killer cell homeostasis. The Journal of Immunology. 2010 Mar; 184(6):2769-75. PMCID: PMC2924750.

26. Zhang X, Yu J. Target recognition-induced NK cell responses. Blood. 2010 Mar; 115(11):2119-20. PMID: 20299516.

27. Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. The PD-1 / PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel, monoclonal anti-PD-1 antibody. Blood. 2010 Sept; 116(13):2286-94. PMCID: PMC3490105.

28. Hughes TL, Becknell B, Freud AG, McClory S, Briercheck E, Yu J, Mao C, Giovenzana C, Nuovo G, Wei L, Zhang X, Gavrilin MA, Wewers MD, Caligiuri MA. Interleukin-1beta selectively expands and sustains IL-22(+) immature human natural killer cells in secondary lymphoid tissue. Immunity. 2010 Jun; 25:32(6):803-14. PMCID: PMC3742307.

29. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010 Apr; 17(4):333-47. PMCID: PMC2917066.

30. Smith MA, Maurin M, Cho HI, Becknell B, Freud AG, Yu J, Wei S, Djeu J, Celis E, Caligiuri MA, Wright KL. PRDM1/Blimp-1 controls effector cytokine production in human NK cells. The Journal of Immunology. 2010 Nov; 185(10):6058-67. PMCID: PMC3864810.

31. Trotta R, Ciarlariello D, Dal Col J, Mao C, Chen L, Briercheck E, Yu J, Zhang J, Perrotti D, Caligiuri MA. The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. Blood. 2011 Feb; 117(8):2378-84. PMCID: PMC3062407.

32. Liu S, Madiai F, Hackshaw KV, Allen CE, Carl J, Huschart E, Karanfilov C, Litsky A, Hickey CJ, Marcucci G, Huja S, Agarwal S, Yu J, Caligiuri MA, Wu L-C. The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis. PLoS ONE. 2011 Mar; 6(3):e17161. PMCID: PMC3048431.

33. Kannan Y, Yu J, Raices RM, Seshadri S, Wei M, Caligiuri MA, and Wewers MD. IB augments IL-12- and IL-18-mediated IFN- production in human NK cells. Blood. 2011 Mar; 117(10):2855–63. PMCID: PMC3062297.

7


34. Yu J *, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu S, Yokohama A, Trotta R, Marcucci G, Benson DM Jr, Loughran TP Jr, Tridandapani S, Caligiuri MA*. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. The Journal of Clinical Investigation. 2011 Apr; 121(4):1456–70. PMCID: PMC3069763. Note: *Co-corresponding author. In news. Highlighted in Faculty of 1000 Biology.

35. Yang X, Peng Y, Yu B, Yu J, Zhou C, Mao Y, Lee LJ, Lee RJ. A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery. Mol Pharm. 2011 Jun 6; 8(3):709-15. PMCID: PMC3599967.

36. McClory S and Yu J. CD25 and IFN- expression in the diagnosis of primary immunodeficiency’s. Journal of Pediatric Biochemistry. 2011; 2(1):1-2.

37. Mehta P, Wavreille AS, Justiniano SE, Marsh RL, Yu J, Burry RW, Jarjoura D, Eubank T, Caligiuri MA, Butchar JP, Tridandapani S. LyGDI, a novel SHIP-interacting protein, is a negative regulator of FcγR-mediated phagocytosis. PLoS ONE. 2011; 6(6):e21175. PMCID: PMC3114867.

38. Yu J . Zoledronate activates NK cells. Blood. 2011 Sept; 118(10):2642-3. PMID: 21903898.

39. Alvarez-Breckenridge CA*, Yu J*, Price R, Wei M, Min Wei, Wang Y, Nowicki O, Ha YP, Bergin S, Hwang C, Fernandez SA, Kaur B, Caligiuri MA, Chiocca EA. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFN- generation. Journal of Virology. 2012 Apr;86(8):4566-77. PMCID: PMC3318659. *These authors equally contributed to this paper.

40. Alvarez-Breckenridge CA, Yu J, Kaur Balveen, Caligiuri MA, Chiocca, EA. Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Advances in Virology. 2012:702839. Epub 2011 Dec 11. PMCID: PMC3263705.

41. McClory S, Hughes T, Freud AG, Briercheck E, Chelsea M, Trimboli A, Yu J, Zhang X, Leone G, Nuovo G, Caligiuri MA. Evidence for a stepwise program of extrathymic T cell development within the human tonsil. The Journal of Clinical Investigation. 2012 Apr; 122(4):1403–1415. PMCID: PMC3314444.

42. Haseley A, Boone S, Wojton J, Yu L, Yoo JY , Yu J, Kurozumi K, Glorioso JC, Caligiuri MA, and Balveen Kaur. Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Research. 2012 Mar; 72:1353–62. PMCID: PMC3366191.

43. Hsu S-H, Wang B, Kota J, Yu J*, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, and Ghoshal K. Essential metabolic, anti-inflammatory and anti-tumorigenic functions for miR-122 in mouse liver. The Journal of Clinical Investigation. 2012 Aug; 122(8):2871-83. PMCID: PMC3408748. *Co-first author.

44. Ren Y, Wei M, Still PC, Yuan S, Deng Y, Chen XZ, Himmeldirk K, Kinghorn AD, Yu J. Synthesis and antitumor activity of ellagic acid peracetate. ACS Med. Chem. Lett.. 2012; 3(8)631–36. PMCID: PMC3505040.

45. Alvarez-Brackenridge CA*, Yu J*, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez S, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri MA, Chiocca EA. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine. 2012; 18(12):1827-34. PMCID: PMC3668784. *Co-first author.

8


46. Alvarez-Brackenridge CA, Yu J, Caligiuri MA, Chiocca EA. Uncovering a novel mechanism of NK cell suppression of glioblastoma virotherapy. Oncoimmunology. 2013 Apr 1; 2(4):e23658. PMCID: PMC3654589.

47. Zhang W, Zhao S, Rao W, Snyder J, Choi JK, Wang J, Khan IA, Saleh NB, Mohler PJ, Yu J, Hund TJ, Tang C and He X. A novel core–shell microcapsule for encapsulation and 3D culture of embryonic stem cells. Journal of Materials Chemistry B. 2013; (7):1002-9. Epub 2012 Nov 23. PMCID: PMC3596163.

48. Park IK, Trotta R, Yu J, Caligiuri MA. The Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development. European Journal of Immunology. 2013 Oct; 43(10):2750-5. PMCID: PMC3829002.

49. Yu J *, Peng Y, Wu L-C, Xie Z, Deng Y, Hughes T, He S, Mo X, Chiu M, Wang QE, Liu S, Grever MR, Chan KK, Liu Z. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PLoS ONE. 2013; 8(2):e55934. PMCID: PMC3572185. *Communicating author.

50. Li Y, Mao W, Fan Z, Li J, Fang Z, Ji X, Hua X, Zong G, Li F, Liu C, Yu J . Synthesis and biological evaluation of novel 1,2,4-triazole containing 1,2,3-thiadiazole derivatives. Chin. Chem. Lett. 2013, 24(12), 1134–36.

51. Peng Y, Dai Y, Hitchcock C, Yang X, Liu L, Sun H-L, Cui R, Wei H, Kim T, Lee TJ, Jeon Y-J, Nuovo GJ, Volinia S, He Q, Yu J, Nana-Sinkam P, Croce CM. Insulin growth factor signaling is regulated by miR-486, an underexpressed microRNA in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2013 Sept; 110(37):15043-48. PMCID: PMC3773758.

52. Yu J *, Freud AG, Caligiuri MA*. Location and cellular stages of NK cell development. Trends in Immunology. 2013 Sep; (13)00112-9. PMCID: PMC3852183. *Communicating author.

53. Wang B, Hsu S, Wang X, Kutay H, Bid H, Yu J, Ganju R, Jacob S, Yuneva M, and Ghoshal K. Reciprocal Regulation of miR-122 and c-Myc in Hepatocellular Cancer: Role of E2F1 and TFDP2. Hepatology. 2014 Feb; 59(2):555-66. doi: 10.1002/hep.26712. Epub 2013 Dec 20. PMCID: PMC4199239

54. Liu Z, Yu J, Carson WE 3rd, Bai XF. The role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response. American Journal of Translational Research. 2013 Aug; 5(5):470-480. PMCID: PMC3745435.

55. Agarwal P, Zhao S, Bielecki P, Rao W, Choi JK, Zhao Y, Yu J, Zhang W, and He X. One-step microfluidic generation of pre-hatching embryo-like core-shell microcapsules for miniaturized 3D culture of pluripotent stem cells. Lab Chip. 2013 Dec; 13(23):4525-33. PMCID: PMC3848340.

56. Wang LS, Kuo CT, Stoner K, Yearsley M, Oshima K, Yu J, Huang TH, Rosenberg D, Peiffer D, Stoner GD, Huang YW. Dietary black raspberries modulate DNA methylation in dextran sodium sulfate (DSS)-induced ulcerative colitis. Carcinogenesis. 2013 Dec; 34(12):2842-50. PMCID: PMC3845896.

57. Zhao R, Han C, Eisenhauer E, Kroger J, Zhao W, Yu J, Selvendiran K, Liu X, Wani AA, Wang Q. DNA DNA damage-binding complex recruits HDAC1 to repress Bcl-2 transcription in human ovarian cancer cells. Molecular Cancer Research. 2014 May; 12(3):370-80. Epub 2013 Nov 18. PMCID: PMC3962721.

9


58. Wang LS, Kuo CT, Huang TH, Yearsley M, Oshima K, Stoner GD, Yu J, Lechner JF, Huang YW. Black raspberries protectively regulate methylation of Wnt pathway genes in precancerous colon tissue. Cancer Prevention Research. 2013 Dec; 6(12);1317-27. PMCID: PMC3902171.

59. Wei R, Zhang W, Fuentes IP, Lei Y, Agarwal P, Weekes B, Li C, Lu X, Yu J, He X. Thermally responsive nanoparticle-encapsulated curcumin and its combination with mild hyperthermia for enhanced cancer cell destruction. Acta Biomater. 2014 Feb;10(2):831-42. PubMed PMID: 24516867; PubMed Central PMCID: PMC4136765.

60. Rao W, Bellotti A, Littrup PJ, Yu J, Lu X, and He X. Nanoparticle-encapsulated doxorubicin enhances cryoablation of cancer stem-like cells. Technology. 02, 28 (2014). DOI: 10.1142/S2339547814500022.

61. Collins SM, Bakan CE, Swartzel GD, Hofmeister HCC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck BL, Hughes T, Yu J, Rice A, Benson DM Jr. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunology, Immunotherapy. 2013 Dec; 62(12);1317-27 PMCID: PMC4134870.

62. He S, Deng Y, Vasu S, Chu J, Yuan S, Zhang J, Fan Z, Hofmeister CC, He X, Marsh HC, Devine SM, and Yu J. FLT3L and Plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome. Biology of Blood and Marrow Transplantation. 2014. Vol. 20 (3):309-313. PMCID: PMC3943635.

63. He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM Jr, Hofmeister C, He X, Ghoshal K, Devine SM, Caligiuri MA, Yu J. MicroRNAs activate natural killer cells through toll-like receptor signaling. Blood. 2013, 121(23):4663-4671. PMCID: PMC3674667. Note: Commentary in Blood. 2013 Jun 6; 121(23):4612-3.

64. Freud AG, Yu J, Caligiuri MA. Human natural killer cell development in secondary lymphoid tissues. Seminars in Immunology. 2014 Apr; 26(2):132-7. doi: 10.1016/j.smim.2014.02.008. PMCID: PMC4010312.

65. Han C, Zhao R, Liu X, Amit S, Gong L, Hua Q, Zhao W, Yu J, and Wang Q. DDB2 suppresses tumorigenicity of ovarian cancer cells by limiting the cancer stem cell population. Molecular Cancer Research. 2014 May. 12(5):784-94. doi: 10.1158/1541-7786.MCR-13-0638. PMCID: PMC4096129.

66. Kim TH, Song J, Kim SH, Krishnavadan Parikh A, Mo X, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, Kwon CH. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro-Oncology. 2014 May 30. pii: nou088. [Epub ahead of print] PMCID: PMC4165421.

67. Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves

D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, Kaur B. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic, anti-tumor effects. Clinical Cancer Research. 2014 May 9. [Epub ahead of print] PMCID: PMC4132885.

68. Ren Y, Lantvit DD, Deng Y, Kanagasabai R, Gallucci JC, Ninh TN, Chai HB, Soejarto DD, Fuchs JR, Yalowich JC, Yu J, Swanson SM, Kinghorn AD. Potent Cytotoxic Arylnaphthalene Lignan Lactones from Phyllanthus poilanei. Journal of Natural Products. 2014 Jun 27; 77(6):1494-504. doi: 10.1021/np5002785. Epub 2014 Jun 12. PMCID: PMC4073661.

69. Rao W, Zhao S, Yu J, Lu X, Zynger DL, He X. Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules. Biomaterials. 2014 Jun 19. pii: S0142-9612(14)00687-5. doi: 10.1016/j.biomaterials.2014.06.011. [Epub ahead of print] PMCID: PMC4405503.

10


70. Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of Cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Molecular Therapy. 2014 Jun 4. doi: 10.1038/mt.2014.101. [Epub ahead of print]. PMCID: PMC4435480.

71. Zhao S, Agarwal P, Rao W, Huang H, Zhang R, Liu Z, Yu J, Weisleder N, Zhang W, He X. Coaxial electrospray of liquid core-hydrogel shell microcapsules for encapsulation and miniaturized 3D culture of pluripotent stem cells. Integrative Biology (Camb). 2014 Jul 18. [Epub ahead of print] PMCID: PMC4138297.

72. Hughes T, Briercheck EL, Freud AG, Trotta R, McClory S, Scoville SD, Keller K, Deng Y, Cole J, Harrison N, Mao C, Zhang J, Benson DM, Yu J, Caligiuri MA. The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells. Cell Reports. 2014 Jun 18. pii: S2211-1247(14)00436-7. doi: 10.1016/j.celrep.2014.05.042. [Epub ahead of print] PMCID: PMC4133146.

73. Deng Y, Chu J, Ren Y, Fan Z, Ji X, Mundy B, Yuan S, Hughes T, Zhang J, Cheema B, Camardo AT, Xia Y, Wu L-C, Wang L-S, He X, Kinghorn AD, Li X, Caligiuri MA, Yu J. The natural product phyllanthusmin enhances IFN-gamma production by human natural killer cells through upregulation of TLR-mediated NF-kappaB signaling. The Journal of Immunology. 2014. 2014 Sep 15; 193(6):2994-3002. PMCID: PMC4162489.

74. Chu J, Deng Y, Benson DM Jr, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine DM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014. 28(4):917-27. doi: 10.1038/leu.2013.279. Epub 2013 Sep 26. PMCID: PMC3967004.

75. Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, Yi L, Wang QN, Kwon C-H, He X, Bai XF, Hofmeister CC, Yu J. . Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clinical Cancer Research. 2014 Mar 27. [Epub ahead of print]. Note: Commentary in Clinical Cancer Research by Dr. Carl H. June’s group, 2014 Jun 11. [Epub ahead of print]. In news. PMCID: PMC4119545.

76. Ren Y., Yuan C., Deng Y., Kanagasabai R., Ninh T.N., Tu V.T., Chai H.B., Soejarto D.D., Fuchs J.R., Yalowich J.C., Yu J., Kinghorn A.D. Cytotoxic and natural killer cell stimulatory constituents of Phyllanthus songboiensis. Phytochemistry. 2015 Jan 14. pii: S0031-9422(14)00546-9. [Epub ahead of print]. PMCID: PMC4333069.

77. Zhang L, Fu J, Sheng K, Li Y, Song S, Li P, Song S, Wang Q, Chen J, Yu J, Wei W. Bone marrow CD11b+ F4/80+ dendritic cells ameliorate collagen-induced arthritis through modulating the balance between Treg and Th17. Int Immunopharmacol. 2015 Jan 22. pii: S1567-5769(15)00021-1. doi: 10.1016/j.intimp.2015.01.014. [Epub ahead of print]. PMID: 25619457.

78. Briercheck EL, Trotta R, Chen L, Hartlage AS, Cole JP, Cole TD, Mao C, Banerjee PP, Hsu HT, Mace EM, Ciarlariello D, Mundy-Bosse BL, Garcia-Cao I, Scoville SD, Yu L, Pilarski R, Carson WE 3rd, Leone G, Pandolfi PP, Yu J, Orange JS, Caligiuri MA. PTEN is a negative regulator of NK cell cytolytic function. The Journal of Immunology. 2015 Jan 16. pii: 1401224. [Epub ahead of print]. PMCID: PMC4319309.

79. Wei R, Wang H, Zhong A, Yu J, Lu X, and He X. Nanodrug-Mediated Thermotherapy of CancerStem-Like Cells. Journal of Nanoscience and Nanotechnology. 2015. In press.

80. Hang J, Alvarez-Breckenridge C, Wang Q-E, and Yu J. TGF- Signaling and Its Targeting for Glioma Treatment. American Journal of Cancer Research. 2015 Feb 15; 5(3):945-55. eCollection 2015. Review. PMCID: PMC4449428.

11


81. Liu J-Q, Zhu X, Liu Z, Yu J, Wu L-C, Bai X. Epstein-Barr virus-induced gene 3-deficiency leads to impaired anti-tumor T cell responses and accelerated tumor growth. OncoImmunology. 2015 Jan 9;4(7):e989137. eCollection 2015 Jul. PMID: 26140252

82. Srivastava AK, Han C, Zhao R, Cui T, Dai Y, Mao C, Zhao W, Zhang X, Yu J, Wang Q-E. Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2015. 2015 Apr 7;112(14):4411-6. doi: 10.1073/pnas.1421365112. Epub 2015 Mar 23. PMCID: PMC4394248.

83. Han J, Chu J, Zhang J, Wang Y, Cohen JB, Victor A, Meisenll WH, Kim S, Grandi P, Wang Q, He X, Nakanoll I, Chiocca EA, Glorioso JC, Kaur B, Caligiuri MA, Yu J. Targeting Wild-Type EGFR and Mutant EGFRvIII with CAR-Engineered NK Cells Efficiently Eliminates Glioblastoma and Its Patient-Derived Stem-like Cells In Vitro and In Vivo. Scientific Reports (nature publisher). 2015 Jul 9;5:11483. doi: 10.1038/srep11483.

84. Yuan S, Haverkos B, Yu J, Su H. Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. Leukemia and Lymphoma. 2016 Jan 6:1-3. PMID:26734914.

85. Wei R, Wang H, Han J, Zhao S, Dumbleton J, Agarwal P, Zhang W, Zhao G, Yu J, Zynger D, Lu X, He X. Augmented Cancer Destruction by Nanodrug Surface-Decorated with Chitosan to Target CD44+ Cancer Stem Cells. ACS Nano. 2015 Jun 23;9(6):5725-40. doi: 10.1021/nn506928p. Epub 2015 May 29.

86. Chen C-P, Piao L, Chen X, Yu J, Rachel M, Schatz F, Lockwood C, Huang S. Interferon gamma expression by decidual cells and natural killer cells at the human implantation site: implications for preeclampsia, spontaneous abortion and intrauterine growth restriction. Reproductive Sciences. 2015 May 11. pii: 1933719115585148. [Epub ahead of print]. PMID: 25963913.

87. Meisen WH, Wohleb ES, Jaime-Ramirez AC, Bolyard CM, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, Caligiuri MA, Godbout J, Kaur B. The impact of macrophage and microglia secreted TNFα on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. Clin Cancer Res. 2015 Mar 31. pii: clincanres.3118.2014. [Epub ahead of print]. PMID: 25829396.

88. Wang H, Zhao S, Agarwal P, Dumbleton J, Wei R, Yu J, Lu X, He X. Multi-layered polymeric nanoparticles for pH-responsive and sequenced drug release. ChemComm. 2015. 2015 May 4; 51(36):7733-6. doi: 10.1039/c5cc01833a. PubMed PMID: 25850616.

89. Zhao, R, Han C, Cui T, Zhang X, He J, Srivastava A; Yu J. Wani A, Wang Q. DDB2 modulates TGF-β signal transduction in human ovarian cancer cells by downregulating NEDD4L. Nucleic Acid Research. 2015 Jun 29. pii: gkv667. [Epub ahead of print]

90. Chang L, Gallego-Perez D, Zhao X, Bertani P, Yang Z, Chiang CL, Malkoc V, Shi J, Sen CK, Odonnell L, Yu J, Lu W, Lee LJ. Dielectrophoresis-assisted 3D nanoelectroporation for non-viral cell transfection in adoptive immunotherapy. Lab Chip. 2015 Jun 24. PMID:26105628.

91. Deng Y, Kerdiles Y, Chu J, Yuan S, Wang Y, Chen X, Mao H, Zhang L, Zhang J, Hughes T, Deng Y, Zhang Q, Wang F, Zou X, Liu C-G, Freud AG, Li X, Caligiuri MA, Vivier E, Yu J*. Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. Immunity. 42, 1-14. March 2015. PMCID: PMC4400836. *Last/Senior author.

92. Deng Y, Yu J. The negative NK cell maturation checkpoint Foxo1. Oncotarget. 2015; 6(32):32301-2. PMID: 26472033.

12


93. Wang H, Agarwal P, Zhao S, Xu RX, Yu J, Lu X, He X. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials. 2015 Dec;72:74-89. PMID: 26344365.

94. Wang H, Agarwal P, Zhao S, Yu J, Lu X, He X. A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of therasnostic agents. Nat Commun. 2015 Dec 1;6:10081. PMCID: PMC4686774.

95. Rao W, Wang H, Han J, Zhao S, Dumbleton J, Agarwal P, Zhang W, Zhao G, Yu J, Zynger DL, Lu X, He X. Chitosan-Decorated Doxorubicin-Encapsulated Nanoparticle Targets and Eliminates Tumor Reinitiating Cancer Stem-like Cells. ACS Nano. 2015 Jun 23;9(6):5725-40. PMID: 26004286

96. Wang H, Yu J, Lu X, He X. Nanoparticle systems reduce systemic toxicity in cancer treatment. Nanomedicine (London, England). 2016; 11(2):103-6. PMID: 26653177.

97. Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). Biol Blood Marrow Transplant. 2016 Jan;22(1):71-9. PMCID: PMC4706501.

98. Wang H, Agarwal P, Zhao S, Yu J, Lu X, He X. A Near-Infrared Laser-Activated "Nanobomb" for Breaking the Barriers to MicroRNA Delivery. Adv Mater. 2016 Jan;28(2):347-55. PMID: 26567892.

99. Deng Y, Deng Y, He X, Chu J, Zhou J, Zhang Q, Guo W, Huang P, Guan X, Tang Y, Wei Y, Zhao S, Zhang X, Wei C, Namaka M, Yi P, Yu J, Li X. Prenatal inflammation-induced NF-κB dyshomeostasis contributes to renin-angiotensin system over-activity resulting in prenatally programmed hypertension in offspring. Sci Rep. 2016 Feb 15;6:21692. doi: 10.1038/srep21692.

100. Zhang L, Chu J, Yu J, Wei W. Cellular and molecular mechanisms in graft-versus-host disease. J Leukoc Biol. 2016 Feb;99(2):279-87. PMID: 26643713.

101. Chen L, Yu J. Modulation of Toll-like receptor signaling in innate immunity by natural products. Int Immunopharmacol. 2016. pii: S1567-5769(16)30040-6.

102. Bao X, Xue S, Hu X, Ma X, Chen F, Chen S, Sun A, Wu D, Yu J, Wu X, Qiu H. Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen. American Journal of Translational Research. 2016, 15;8(2):653-61. eCollection 2016.

103. Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, Chiocca EA, Kaur B, Caligiuri MA, Yu J. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Research. 2015 Dec 15;75(24):5273-82. PMCID: PMC4681611.

104. Vasu S, Shun He, Cheney C, Gopalakrishnan B, Rajeswaran M, Lozanski G, Mo X, Veronica G, Whitman S, Renate K, Christian K, Bucci D, Lucas D, Yu J, Caligiuri MA, Blum W, Paul JA, Eric B, Bjoern R, Karl-Heinz H, Marcucci G, Muthusamy R. Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts. Blood. 2016 Mar 24. pii: blood-2015-11-680546. [Epub ahead of print].

13


105. Zhu X, Liu Z, Liu J-Q, Zhu J, Zhang J, Davis J, Chu J, Yu J, Zhou J, Li M-S, Bai X-F. Systemic delivery of IL-27 by an adeno-associated viral vector inhibits T cell mediated colitis and inducing multiple inhibitory pathways in T cells. Journal of Leukocyte Biology. 2016 Apr 22. pii: jlb.3A1215-540R. [Epub ahead of print].

106. Xiao R, Bergin SM, Huang W, Slater AM, Liu X, Judd RT, Lin ED, Widstrom KJ, Scoville SD, Yu J, Caligiuri M, Cao L. Environmental and genetic activation of hypothalamic BDNF modulates T-cell immunity to exert an anticancer phenotype. Cancer Immunology Research. 2016 Apr 4. pii: canimm.0297.2015. [Epub ahead of print]. PMID: 27045020

107. Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, Chen L, Wang Y, Wang H, Yi L, J. Elder B, Wang Q, He X, Kaur B, Yu J. A Combinational Therapy of EGFR-CAR NK Cells and Oncolytic Herpes Simples Virus 1 for Breast Cancer Brain Metastases. Oncotarget. 2016 Apr 1. doi: 10.18632/oncotarget.8526. [Epub ahead of print]In press.

108. Wang H, Agarwal P, Zhao S, Yu J, Lu X, He X. Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells. Biomaterials. 2016, 26;97:62-73. doi: 10.1016/j.biomaterials. 2016.04.030. [Epub ahead of print].

109. Ren Y, Yu J, Douglas Kinghorn A. Development of anticancer agents from plant-derived sesquiterpene lactones. Curr Med Chem. 2016 May 10. [Epub ahead of print].

110. Zhang Q, Deng Y, Lai W, Guan X, Sun X, Han Q, Wang F, Pan X, Ji Y, Luo H, Huang P, Tang Y, Gu L, Dan G, Yu J, Namaka M, Zhang J, Deng Y, Li X. Maternal inflammation activates ROS-p38 MAPK predisposes offspring to heart damages caused by isoproterenol via imbalance of ROS generation and elimination. Scientific Reports. 2016. In press.

111. Zhao S, Zhang L, Han J, Chu J, Wang H, Chen X, Wang Y, Tun N, Lu L, Bai X, Martha Y, Devine S, He X, Yu J. Conformal nanoencapsulation of allogeneic T cells mitigates graft-versus-host disease and retains graft-versus-leukemia activity. ACS Nano. ACS Nano. 2016 May 25. [Epub ahead of print]. PMID: 272248532016.

Seminars and Invited Presentations

Local

1. Elucidation and Modulation of Natural Killer Cells for Application in Cancer Treatment, Department of Pathology, The Ohio State University. May, 2012.

2. Elucidation and Modulation of Natural Killer Cells for Cancer Treatment. The Ohio State Biochemistry Program (OSBP). January, 2013.

3. MicroRNAs Activate Natural Killer Cells through Toll-like Receptor Signaling. Immunology Seminar, The Ohio State University. April, 2013.

Talks at Regional, National, and International Conferences or Institutes

14


1. Elucidation of The Molecular Mechanisms by Which Inflammatory and Anti-Inflammatory Cytokines Regulate Interferon (IFN)- Production. The 46th Annual Meeting of the American Association of Hematology. San Diego, CA, 2004 (oral presentation).

2. Elucidation and Modulation of Natural Killer Cells for Application in Cancer Treatment and Prevention. Medical College of Wisconsin. Milwaukee, WI, 2011.

3. Imbalance between Pro-inflammation and Anti-inflammation Mediators Leads to Cancer Development. Chinese Anti-inflammation and Immune-Pharmacology Society Annual Meeting. Guangzhou, China, December, 2012.

4. FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome. The 55th Annual Meeting of the American Association of Hematology. New Orleans, Louisiana, United States. December, 2013

5. CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells and T Cells Enhance In Vitro and In Vivo Anti-Tumor Activity against Human Multiple Myeloma. The 55th Annual Meeting of the American Association of Hematology. New Orleans, Louisiana, United States. December, 2013.

6. Arming NK Cells for Cancer Treatment. Indiana University-Purdue University Indianapolis. Indianapolis, Indiana. April, 2014.

7. Targeting Tumor Antigens with Chimeric Antigen Receptor (CAR)-Engineered Natural KillerCells for Treatment of Multiple Myeloma and Glioblastoma Multiforme. 11th International Conference on Innate Immunity. Olympia, Greece. June, 2014.

8. Immunotherapy of Hematological Malignancies through Transplantation of Nanoparticle-Encapsulated Allogeneic T cells and Adoptive Transfer of Chimeric-Antigen Receptor (CAR)-Engineered NK and T cells. The 19th Congress of Asia Pacific Blood and Marrow Transplantation Group (APBMT). Hangzhou, China. October, 2014.

9. Natural Killer Cell Biology and Its Application for Cancer Treatment. 18th Annual Meeting of the Translational Research Cancer Centers Consortium (TRC3). Seven Springs Mountain Resort, Seven Springs, Pennsylvania. February, 2015.

10. Use of Hematopoietic Stem Cell Transplantation and Natural Killer Cells for Treatment of Cancer. Chinese Hematopoietic Stem Cell Transplantation Association Annual Meeting, the Chinese Society of Hematology. Suzhou, China. October, 2015

11. Mobilizing and Driving Immune Cells for Cancer Treatment. American Association of Blood Banks (AABB) Annual Meeting. Anaheim, California. October, 2015

12. Modulation of NK Cell Activity in the Setting of Oncolytic Virotherapy and with a Chimeric Antigen Receptor. The 57th Annual Meeting of the American Association of Hematology. Orlando, Florida. December, 2015.

13. Advances of CAR NK cells. The 5th International Cell Therapy Conference. Shandong Stem Cell and Regeneration Medicine Committee. Jinan, China. May, 2016.

14. CS1 CAR T and CAR NK for myeloma therapy. The Second Annual Immuno-Therapy in Myeloma Scientific Workshop. Boston, Massachusetts. May, 2016.

Research Support

15


R01s from the National Institutes of Health (NIH)

U01 from the National Cancer Institute, NIH

Medical Research Award from Gabrielle Angel Foundation

The American Cancer Society Scholar Grant

Start-up Funds from The Ohio State University Comprehensive Cancer Center

The Ohio State University Comprehensive Cancer Center Pelotonia Grants

16

NAME: Jianhua Yu, Ph - Ohio State University€¦ · Web [email protected]. ... World...

Documents

Transcript of NAME: Jianhua Yu, Ph - Ohio State University€¦ · Web [email protected]. ... World...